Physician profile
Simon Vinarsky
NPI 1245268838
$2,619.05
in general payments reported to CMS, 2019-2025
32 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $130 · 2021: $1,069 · 2022: $516 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $306.87 | 2019-2022 | |
| Incyte Corporation | $266.78 | 2019-2021 | |
| Janssen Biotech, INC. | $237.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.29 | 2019-2022 | |
| Genentech USA, INC. | $195.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.87 | 2022 | |
| Geron Corporation | $135.00 | 2025 | Rytelo |
| Eisai INC. | $133.03 | 2020-2021 | |
| Seagen INC. | $131.65 | 2019-2021 | |
| Myovant Sciences INC. | $115.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $114.17 | 2019-2021 | |
| Kite Pharma, INC. | $85.26 | 2021 | |
| Caris Mpi, INC. | $74.77 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $72.39 | 2020-2022 | |
| Tersera Therapeutics LLC | $67.90 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.95 | 2020-2022 | |
| Taiho Oncology, INC. | $32.93 | 2019 | |
| Lilly USA, LLC | $24.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.64 | 2021 | |
| Daiichi Sankyo INC. | $19.70 | 2019 | |
| Celgene Corporation | $17.45 | 2022 | |
| Astellas Pharma US INC | $16.67 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $16.65 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.36 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.10 | 2019 | |
| Puma Biotechnology, INC. | $13.05 | 2019 | |
| Merck Sharp & Dohme LLC | $12.16 | 2021 | |
| Exelixis INC. | $12.09 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.79 | 2021 | |
| Verastem, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Vinarsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.